Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA’s Zohydro ER Headache Worsening: States, DOJ Question Approval

Executive Summary

Massachusetts’ ban on the single-entity hydrocodone signals a new kind of activism by states, and there even appears to be disunity within the Obama administration about the value of the long-acting opioid as Attorney General Holder tells Congress he is “a little baffled” by FDA’s approval and will be evaluating the basis for the decision.

You may also be interested in...



What Might FDA Do Post Roe? Eliminate Mifepristone REMS

Attorneys say the biggest step FDA could take to expand access to medication abortion would be to eliminate REMS requirement for mifepristone. Timeline notes steps Biden administration and Congress have taken since the Supreme Court’s ruling overturning the right to an abortion.

Mifepristone Access Imperiled By Supreme Court’s Draft Decision Overturning Abortion Rights

Clinicians in states that ban abortion could face criminal prosecution for providing mifepristone. Access to medical abortion ‘is not a panacea’ if the court overrules Roe v. Wade as people using the drug face risks from aggressive prosecutors, ACLU attorney says.

The Short And Controversial Life Of Zohydro Comes To An End

US FDA’s approval of the opioid over resounding opposition of an advisory committee has haunted the agency, and it has imperiled both of Robert Califf’s nominations to be commissioner. The latest company to own Zohydro stopped selling it and FDA withdrew approval of its NDA.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS056029

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel